COPD is the fourth-leading cause of death in the United States, and cigarette smoking has been proven to be the most important environmental contributor. DNA methylation varies with aging and with environmental exposures such as cigarette smoking, and is a critical mediator of gene expression. Additionally, there are data to suggest that DNA methylation patterns are influenced by DNA polymorphisms. Although widely studied in cancers, including lung cancer, the wide-scale investigation of variable methylation in COPD and the correlation with polymorphisms and gene expression have not been comprehensively performed. COPD has both local pulmonary and systemic manifestations, all of which are likely impacted by a combination of genetic, genomic and epigenetic pathways. We hypothesize that characterization of genome-wide DNA methylation marks will provide important scientific insights into COPD. We also hypothesize that characterizing genome-wide DNA methylation marks correlated with IREB2, HHIP and FAM13A variants may provide important insights into regulation of these three COPD candidate genes. To address these two hypotheses, the broad goals of this project include: 1) to identify methylation signatures that discriminate COPD susceptibility and COPD severity and 2) to use comparative epigenetic to identify methylation marks that are altered by cigarette smoke exposure and likely impact the development of COPD and its component processes, emphysema and airway disease. In this project, genome-wide methylation patterns will be characterized for lung tissue and blood DNA from human subjects in our Lung Tissue Population. Methylation patterns will also be characterized for murine lung DNA after in vivo exposure of wild-type C57BL/6 {susceptible) and NZW/LacJ (resistant) mice to cigarette smoke. We will use statistical modeling and comparative epigenetics to select COPD gene candidates to replicate using pyrosequencing methods in the Bronchoscopy Population, a second human cohort. This project will characterize DNA methylation marks important to COPD and will assess the epigenetic impact of variation in IREB2, HHIP and FAM13A as key COPD candidate genes. We will use comparative, translational and integrative genetics, genomics and epigenomics to identify functional features of COPD susceptibility genes. We expect methylation marks with replicated associations will provide novel insights into the pathobiology of COPD and the genetic context that influences the epigenomic impact of cigarette smoking. Lastly, we will integrate SNP variation, methylation marks and gene expression data to define the most comprehensive causal model of COPD.

Public Health Relevance

Investigation of variable patterns of gene methylation may provide important insights into risks for smoking related diseases. Epigenetic marks such as DNA methylation have been targets for novel diagnostics and therapeutic innovations in human disease. Identifying unique methylation signatures for COPD may result in a clinically relevant biomarker to enable earlier diagnosis and novel therapies for the treatment of COPD/ennphysema.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL105339-02
Application #
8381264
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
2
Fiscal Year
2012
Total Cost
$353,266
Indirect Cost
$130,002
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Busch, Robert; Qiu, Weiliang; Lasky-Su, Jessica et al. (2016) Differential DNA methylation marks and gene comethylation of COPD in African-Americans with COPD exacerbations. Respir Res 17:143
Putman, Rachel K; Hatabu, Hiroto; Araki, Tetsuro et al. (2016) Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA 315:672-81
Hardin, M; Cho, M H; McDonald, M-L et al. (2016) A genome-wide analysis of the response to inhaled β2-agonists in chronic obstructive pulmonary disease. Pharmacogenomics J 16:326-35
Cloonan, Suzanne M; Choi, Augustine M K (2016) Mitochondria in lung disease. J Clin Invest 126:809-20
Lao, Taotao; Jiang, Zhiqiang; Yun, Jeong et al. (2016) Hhip haploinsufficiency sensitizes mice to age-related emphysema. Proc Natl Acad Sci U S A 113:E4681-7
Jiang, Zhiqiang; Lao, Taotao; Qiu, Weiliang et al. (2016) A Chronic Obstructive Pulmonary Disease Susceptibility Gene, FAM13A, Regulates Protein Stability of β-Catenin. Am J Respir Crit Care Med 194:185-97
Hardin, Megan; Foreman, Marilyn; Dransfield, Mark T et al. (2016) Sex-specific features of emphysema among current and former smokers with COPD. Eur Respir J 47:104-12
Chang, Yale; Glass, Kimberly; Liu, Yang-Yu et al. (2016) COPD subtypes identified by network-based clustering of blood gene expression. Genomics 107:51-8
Busch, Robert; Han, MeiLan K; Bowler, Russell P et al. (2016) Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort. BMC Pulm Med 16:28
Wang, Longfei; Lee, Sungyoung; Gim, Jungsoo et al. (2016) Family-Based Rare Variant Association Analysis: A Fast and Efficient Method of Multivariate Phenotype Association Analysis. Genet Epidemiol 40:502-11

Showing the most recent 10 out of 85 publications